



**TML: CS: BSE/NSE CORR: 2023-24**

**10<sup>th</sup> November, 2023**

The Manager  
Corporate Relationship Department  
BSE Limited  
Floor 25, Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai- 400001  
Scrip Code – 530199

The Manager – Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East), Mumbai- 400051  
Symbol: THEMISMED

**Sub: Press Release**

Ref: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the “SEBI Listing Regulations”)

Dear Sir/Madam,

In terms of Regulation 30 of the SEBI Listing Regulations, we are enclosing herewith a copy of the press release titled - **“Themis Medicare Launches REMITHEM® – REMIFENTANIL Injection A Novel Narcotic Analgesic for use during induction of anesthesia, during immediate post-operative period and in monitored anesthesia care”**.

Kindly take this on record.

Thanking you,

Yours faithfully,

**For Themis Medicare Ltd.**

**Sangameshwar Iyer**  
**Company Secretary & Compliance Officer**

## **Themis Medicare Limited**

**Corporate Office:** 11/12 Udyog Nagar, S V Road, Goregaon (W), Mumbai – 400 104, India  
**\*Tel.:** 91-22-67607080 **\*Fax:** 91-22-67607070/ 28746621  
**Regd. Office:** Plot No. 69-A, G.I.D.C., Industrial Estate, Vapi-Gujarat  
**CIN No.:** L24110GJ1969PLC001590 **\*Tel/ Fax No.:** **Regd. Off.:** 0260-2431447/ 2430219  
**\*E-mail:** themis@themismedicare.com **\*Website:** www.themismedicare.com



## PRESS NOTE CONTENT

Mumbai, India: 10<sup>th</sup> November, 2023

**“Themis Medicare Launches REMITHEM<sup>®</sup> – REMIFENTANIL Injection A Novel Narcotic Analgesic for use during induction of anesthesia, during immediate post-operative period and in monitored anesthesia care”**

**Themis Medicare Ltd. (Themis)**, a Pharmaceutical company headquartered in Mumbai with a legacy of over 50 years of making new treatment options available, announced the launch of a novel Opioid Injectable Analgesic REMIFENTANIL under its brand name **REMITHEM<sup>®</sup>** in the Indian market **for use during induction of anesthesia, during immediate post operative period and in monitored anesthesia care.**

**Remifentanil<sup>®</sup> was first approved in USA in 1996 and** has wide clinical usage & acceptance around the world in major markets including USA, Europe, Japan and other countries and is also well published.

**Themis Medicare Limited** has done pioneering work by conducting phase III trials at 13 centers in India before getting REMIFENTANIL approved by the regulators.

**REMITHEM<sup>®</sup>** Remifentanil is considered to be a Dial In Opioid Analgesic as it has a quick onset of action, while it also has a very short context sensitive half-life enabling in addition a quick offset of action, while reducing the overall time in the OT and Post operative care room.

Clinical studies have documented that **REMITHEM<sup>®</sup>** is better as compared to Fentanyl injection the currently used Standard of Care from an overall pharmacokinetic, hemodynamic and safety perspective.

Various studies also suggest that when used with other anesthetic agents **REMITHEM<sup>®</sup>** may have synergy and as a result help reduce the dosage of other concomitant anesthetic agents.

**REMITHEM<sup>®</sup>** being an Opioid Analgesic would be only available for use in hospitals which have the necessary licenses/permissions to use Opioid Analgesics.

Based on the product's benefit, **REMITHEM<sup>®</sup> appears to offer a unique therapeutic option to Anesthesiologists for use during induction of anesthesia, during immediate post operative period and in monitored anesthesia care.**

## **Themis Medicare Limited**

**Corporate Office:** 11/12 Udyog Nagar, S V Road, Goregaon (W), Mumbai – 400 104, India

**\*Tel.:** 91-22-67607080 **\*Fax:** 91-22-67607070/ 28746621

**Regd. Office:** Plot No. 69-A, G.I.D.C., Industrial Estate, Vapi-Gujarat

**CIN No.:** L24110GJ1969PLC001590 **\*Tel/ Fax No.:** **Regd. Off.:** 0260-2431447/ 2430219

**\*E-mail:** themis@themismedicare.com **\*Website:** www.themismedicare.com



In the pre-launch meetings conducted by Themis Medicare Limited leading anesthesiologists at Chennai, Cochin and Delhi expressed the view that with launch of **REMITHEM**® “**The Wait is Over**”.

Speaking at the release, *Dr. Sachin Patel, Managing Director& CEO* of Themis Medicare Ltd. said, “Our endeavor has always been to provide world class medicines that benefit patients and make healthcare far, far more effective. **REMITHEM**® will be promoted by a highly trained field force which is experienced in selling Critical care products including a range of Opioids in the hospitals across the country.”

According to Themis Medicare Limited, **REMITHEM**® will be available as 1 mg and 2 mg vials for Injection.

With a strong R&D backup, skilled domestic & export teams, and state-of-the-art manufacturing sites, the endeavor at Themis has always been to support the medical fraternity with solutions for major unmet medical needs and **REMITHEM**® launch is yet another step in that direction.

#### **About Themis Medicare Ltd.**

Themis Medicare was incorporated in 1969 as a joint venture partnership at Vapi. Today, it is one of the fastest growing pharma companies specializing in the development of complex molecules. With strong research focus on injectables, complex generic products and drug- delivery systems, the Company has evolved into being a formidable player in the complex generics space. It has a diversified business model with presence across the B2B model and strong presence in domestic B2C market. The Company also has a significant export presence in the RoW geographies. The qualified and experienced Management team is complemented by highly skilled R&D workforce. The Company has three vertically integrated manufacturing facilities, of which two are focused on developing APIs –one each involved in manufacturing Synthetic API and Fermentation based API, and 1 is involved in manufacturing of Finished Dosage Formulations. Themis Medicare offers products in various dosage forms in multiple therapeutics areas with leadership in Pain Management and Critical Care. The Company has a strategy to focus and grow its injectable portfolio and develop its NDDS presence.

## **Themis Medicare Limited**

**Corporate Office:** 11/12 Udyog Nagar, S V Road, Goregaon (W), Mumbai – 400 104, India

**\*Tel.:** 91-22-67607080 **\*Fax:** 91-22-67607070/ 28746621

**Regd. Office:** Plot No. 69-A, G.I.D.C., Industrial Estate, Vapi-Gujarat

**CIN No.:** L24110GJ1969PLC001590 **\*Tel/ Fax No.:** **Regd. Off.:** 0260-2431447/ 2430219

**\*E-mail:** themis@themismedicare.com **\*Website:** www.themismedicare.com